<DOC>
	<DOC>NCT02678598</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients with invasive fungal infections caused by Candida sp. or Aspergillus sp. (fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.</brief_summary>
	<brief_title>A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients who received Micafungin as empirical antifungal therapy, preemptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy Patients received Micafungin treatment at least 1 dose Patients received Micafungin treatment combined with other antifungal drugs at the same time Neither efficacy or safety can be evaluated because of missing data, confused record</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Candida</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Antifungal</keyword>
</DOC>